| Business Summary | | Cell
Genesys,
Inc.,
a
gene
therapy
company,
is
focused
on
the
development
and
commercialization
of
cancer
vaccines
and
gene
therapies
to
treat
major,
life-threatening
diseases.
The
Company
is
conducting
multicenter
clinical
trials
for
its
GVAX
cancer
vaccines
in
prostate
cancer,
lung
cancer,
pancreatic
cancer
and
myeloma,
and
expects
to
initiate
additional
GVAX
vaccine
trials
in
many
of
these
cancers,
as
well
as
leukemia,
during
2001.
GVAX
vaccine
for
prostate
and
lung
cancer
are
being
developed
through
a
worldwide
collaboration
with
the
pharmaceutical
division
of
Japan
Tobacco.
In
addition,
Cell
Genesys
has
a
number
of
product
opportunities
at
the
preclinical
stage,
including
in
vivo
gene
therapies
for
cancer,
hemophilia
and
cardiovascular
disease.
The
Company's
majority-owned
subsidiary,
Ceregene,
Inc.,
is
focused
on
the
development
of
gene
therapies
for
neurologic
disorders.
Cell
Genesys
also
continues
to
hold
a
10.5%
equity
ownership
its
former
subsidiary,
Abgenix,
Inc. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Cell
Genesys,
Inc.
is
focused
on
the
development
and
commercialization
of
gene
therapies
to
treat
cancer
and
other
major,
life-threatening
diseases.
For
the
six
months
ended
6/30/01,
revenues
rose
4%
to
$10
million.
Net
loss
before
accounting
change
totaled
$4.9
million,
vs.
income
of
$136.1
million.
Revenues
reflect
increased
collaborative
agreements.
Loss
reflects
the
absence
of
a
$190.2
million
realized
gain
on
the
sale
of
Abgenix
stock. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Stephen Sherwin, M.D., 52 Chairman,
CEO | $665K | $2.1M | Joseph Vallner, Ph.D., 54 Pres,
COO | 385K | -- | Matthew Pfeffer, 43 CFO,
VP | 238K | -- | Christine McKinley, 47 VP
of HR | 236K | 1.5M | Dale Ando, M.D., 47 VP
of Clinical Research | 270K | 2.9M | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|